Written by Dan Cohen and Scott Matusow Cytokinetics (NASDASQ:CYTK) looks to turn around their fortunes following last year’s unsuccessful readout of Tirasemtiv in …
ArQule, Inc. (NASDAQ:ARQL) shares tumbled nearly 20% this morning after investors learned that the company’s METIV-HCC phase 3 study of tivantinib in hepatocellular carcinoma (HCC) …
